The effect of nedocromil sodium on the early and late reaction and allergen-induced bronchial hyperresponsiveness.
Bronchial hyperresponsiveness (BHR) to methacholine was studied in 14 patients with asthma and five healthy control subjects, with and without pretreatment with nedocromil sodium, 3 and 24 hours after allergen challenge. Eleven patients demonstrated a dual asthmatic response. A significant decrease in the provocative concentration causing a 20% fall in FEV1 was found from a geometric mean starting value of 1.18 mg/ml on the control day to 0.24 mg/ml (p less than 0.001) and to 0.17 mg/ml (p less than 0.001) 3 and 24 hours after allergen challenge. A significant correlation was observed between the increased BHR at 3 hours and the magnitude of the late response (r = -0.57; p less than 0.05). Nedocromil sodium (6 mg) significantly inhibited the increase in BHR, 1 mg/ml (p less than 0.001) at 3 hours and 0.50 mg/ml (p less than 0.001) at 24 hours. Nedocromil sodium shifted the severity of the early allergic reaction (EAR) from mean -34.8% to -6.9% and inhibited the later allergic reaction (LAR) from -30.5% to +0.4% (p less than 0.005). From the study can be concluded that nedocromil sodium inhibits the EAR and LAR and the allergen-induced increase in BHR. The inhibitory effect of nedocromil sodium on the LAR may be related to its ability to inhibit the increased BHR before the development of the LAR.
Aalbers
R
R
Department of Allergology, University Hospital, Groningen, The Netherlands.
Kauffman
H F
HF
Groen
H
H
Koëter
G H
GH
de Monchy
J G
JG
D000485:Allergens / Q000276:immunology*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy / Q000276:immunology; D001980:Bronchi / Q000187:drug effects* / Q000276:immunology; D001985:Bronchial Provocation Tests; D004391:Dust; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000188:drug therapy* / Q000276:immunology; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D016210:Methacholine Chloride; D008925:Mites / Q000276:immunology; D017835:Nedocromil; D015363:Quinolones / Q000627:therapeutic use*; D013997:Time Factors
D000485:Allergens; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004391:Dust; D015363:Quinolones; D017835:Nedocromil; D016210:Methacholine Chloride